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Abstract
Immune cell therapies have been studied in numerous clinical trials using Advanced 
Therapy Medicinal Products (ATMP) against a number of diseases having no or inadequate 
alternative therapies available, for example, various cancer types, cerebral stroke, cardiac 
infarction, severe autoimmune disorders, or chronic infections. Despite the enormous num-
ber of positive observation in ex vivo or animal studies, convincing results in clinical stud-
ies remain scanty. The chapter presents a survey and reveals that the manufacturing of 
immune cells especially for clinical trials is until today primarily performed using archaic, 
scarcely controlled, and incomparable processes and methods. A deeper characterization 
of ex vivo expanded immune cells is urgently needed not only on the level of a few recep-
tors and ligands on the cell surface but also with respect to the ever-contained subtypes in 
an expanded immune cell population, the pattern of secreted effector molecules, and their 
amounts over time and influences from in vivo components on them.
Keywords: immune cells, cell therapy, expansion technologies, T cells, TIL, NK cells, 
MSC, GMP production, ATMP
1. Introduction
Immune cells have been the key players as well as glamor of active clinical research of the cur-
rent decade. T-lymphocytes (T cells), tumor-infiltrating lymphocytes (TIL), chimeric antigen 
receptor T cells (CAR-T cells), natural killer cells (NK cells), mesenchymal stem/stromal cells 
(MSC) from bone marrow, umbilical cord blood, umbilical cord tissue layers, placenta, and 
adipose tissues are the main objects studied in immune cell therapies for various  diseases. 
Publications from numerous preclinical studies and developments on isolation, expansion, 
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activation, and phenotyping of the different immune cells are increasing exponentially over 
the last years. Numerous clinical trials have been conducted or are running, evaluating 
immune cells as novel Advanced Therapy Medicinal Products (ATMP) therapy against num-
ber of diseases having no or inadequate alternative therapies available (see Table 1) [2]. There 
is a strong belief that progress for many severe, life-threatening diseases with bad prognosis 
that happens in various fulminant cancer types, cerebral stroke, cardiac infarction, severe 
autoimmune disorders, or chronic infections can either be effectively treated or even cured 
by immune cell therapy when applied optimally in combinations with other conventional 
therapies. It is not clear if this belief is justified at this juncture with adequate evidence. It 
is crucial to critically analyze this question for an insight to address the stumbling blocks to 
make significant advances in this field.
Isolated immune cells consistently display effectiveness against cancer cells, micro-organisms, 
inhibition of inflammation parameters, etc., in ex vivo test systems and often also in in vivo mouse 
models. The enormous number of positive observations are very encouraging and propel the 
immune cell research field and drives growing numbers of clinical trials. However, convincing 
results in clinical studies remain scanty over decades despite the wider engagement and R&D 
investments [3–6]. Several tumor-infiltrating lymphocytes (TIL) as well as treating therapy-
resistant hematopoietic and solid tumor cancers with specific activated CAR-T cells show long-
lasting benefits in otherwise grim cases [7, 8]. In cancer of the hematopoietic system, immune 
cell therapy has demonstrated its real potency and has become an effective standard therapy [9]. 
Leukemia and similar forms of cancer of the hematopoietic system can be cured with disease-
free survival or without progression in a high percentage through the transplantation of bone 
marrow cells from healthy and genetically compatible (allogeneic) donors.
Immune cell type Clinical trials in total Open clinical trials Clinical trials
Europe total US total China total
T-lymphocytes 2343 723 116 401 184
TIL 77 27 4 17 0
CAR-T-lymphocytes 170 123 7 40 78
NK cells 407 140 10 49 62
MSC 339 134 34 29 39
BM-MSC 104 46 12 12 7
UC-MSC 54 24 2 0 16
UCB-MSC 7 3 0 0 2
AT-MSC 20 6 1 1 2
Total number of clinical trials worldwide and in several geographical regions as registered on www.clinicaltrials.
gov/, accessed on Feb 15, 2017 [1]. TIL: tumor-infiltrating lymphocytes; CAR-T-lymphocytes: chimeric antigen receptor 
lymphocytes; MSC: mesenchymal stromal cells; BM-MSC: bone marrow MSC; UC-MSC: umbilical cord MSC; AT-MSC: 
adipose tissue MSC.
Table 1. Current ongoing clinical studies with selected immune cells.
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It is important to reflect into the realities of the limited clinical success in contrary to the prom-
ising in vitro or ex vivo findings. All the inadequate, inconsistent clinical outcomes observed 
using immune cells in vivo following ex vivo expansion and all the knowledge gained with 
immune cells in the numerous clinical trials and individual or small clinical studies using 
hospital exemptions might have to do with underestimating the key issues with respect to 
identity, quality, potency, and functionality of the used cells. All the characteristics of the cells 
as well as influences from production technology, characterization methods, etc. are seldom 
taken into broader account in robust ways before cells are infused as therapeutics. This will 
be highlighted in the following sections.
2. Requirements and existent challenges in producing immune cells  
for cell therapy
Looking on the methods, technologies, specific equipment, and analytical tools, it is obvious 
that cell expansion technologies suited for producing specific immune cells for individual 
immune cell therapy are the weak side of the story. The actual knowledge on the potentials of 
immune cells is so far only scarcely translated into practical technical solutions, broadly avail-
able methods, congruent with the capabilities. That is true for standardized and reproducible 
expansion of defined immune cell preparations as well as for estimates and methods of mea-
suring specific functionalities of an expanded immune cell population against tumor cells, 
infections, or inflammations. Moreover, there are also missing generally available methods 
and techniques for fast and precise measurement of homogeneity of a cell population, of char-
acteristics of sub populations, and single cells [10–13]. All these aspects appear to be widely 
responsible for the limited progress by these very promising new therapies. Several key issues 
are critical determinants for ATMP cell therapy which are enumerated below.
• Isolation of specific immune cells from blood or tissues and initial expansion steps are per-
formed with broadly differing methods. The procedures need to be better standardized and 
harmonized with the validation of the composition of the starting populations of immune cells.
• Ideally, expansion of immune cells should be started with a pure population of specific im-
mune cells. When a mixture of cells (like PBMC) or a piece of tissue are taken, isolation of 
cells should be performed in a defined procedure consistently.
• Immune cells for individual cell therapies must be produced in standardized, reproduc-
ible, and GMP conform processes. Amounts of 109 to more than 1010 cells of a pure immune 
cell population are assumed as a single optimal therapeutic dose. The manufacturing pro-
cess with newer available technologies for each cell type is yet to be established coherently 
for the clinical trials.
• Standardized and consistent production processes need to be dynamically controlled and 
documented during the entire culturing process. Only a few production technologies are 
currently on the market fulfilling all of the abovementioned requirements and thus are 
capable of manufacturing individual cell therapeutics as ATMP.
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• To ensure reproducibility of immune cell production for cell therapies, process conditions 
have to be controlled, evaluated, documented, and validated. Continuous dynamic control 
of temperature, pH, and pO
2
 in the medium during the immune cell expansion process 
is indispensable. Glucose and lactate concentration as lead substances for substrates and 
metabolites should also be under steady control during processing.
• All immune cells can be expanded in a common basic medium. However, until now sup-
plementing with serum or thrombocyte lysate is still indispensable. For optimized growth 
over a prolonged period of time and mass production of the different immune cell speci-
men, supply with nutrients, gases, and supplements should normally take place in a dy-
namic, homogenous, and stress-free process to maintain differentiation status, phenotype, 
and function of those cells within physiological ranges.
• Irradiated feeder cells are used to achieve an initial expansion with low numbers of isolated 
effector cells and to increase cell expansion when using insufficient technical equipment 
(e.g., wells or flasks with uncontrolled processing). Appropriate novel technologies can 
possibly eliminate the use of feeder cells.
• Important criteria of immune cells for therapies are a deeper marker profiling and stan-
dard estimates for chemokine and cytokine production efficiency (paracrine factors). Both 
together are decisive measures for the potency and functional power of immune cell popu-
lations/subpopulations for the intended effects. Standardized and comparable values as 
correlate measures should be mandatory for immune cell therapeutics which need to be 
established.
• Subpopulations or even monoclonal immune cells can be produced by guiding an ex vivo 
expansion process through specific activation/inhibition/triggering/priming the cells. Re-
spective coating/fixed antibodies at bioreactor surface, O
2
 concentration in culture condi-
tions (hypoxic/normoxic/hyperoxic), flow dynamics of medium have to be explored, com-
pared, and optimized for each condition.
• Immune cells for therapies have to fulfill all the conditions as well as national regulatory re-
quirements and international standards for approval for clinical trial use as investigational 
medicinal product (IMP) and/or market authorization as ATMP. All the manufacturing 
steps of an individual immune cell preparation must still be performed in a Clean Room A 
containment for most processes used for production that consist of more or less open steps.
• Current international regulatory standards are in process of evolution as ATMP cannot 
simply follow the standard of a chemical compound which is a fixed inert molecule, where-
as a cell is a living dynamic entity with too many variables and dynamic potentials. It is 
being considered that regulations on individual cell therapeutics might be registered as 
distinct category and might be oriented on indications. This needs to mature in course of 
time to bring ATMP cell therapy for real clinical use in routine practice.
• Faster scientific progress, earlier availability, access, and affordable prices of immune cell 
ATMP can only be achieved when advanced production technologies can be utilized or 
further developed to realize these desired objectives.
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3. Techniques and methods used for isolation and expansion of  
immune cells
Blood from patients or donors is a convenient starting material for cell purification and expan-
sion. Table 2 shows the number of different immune cells contained in a 200 ml sample of 
peripheral blood. A simple gradient centrifugation of a blood sample is normally taken to 
obtain “peripheral blood mononuclear cells” (PBMC). Ex vivo expansion of the total frac-
tion of T cells, NK, and other cell types within PBMC is possible and is the most commonly 
used technique to provide starting material for subsequent ex vivo expansion of the different 
immune cell types.
Apheresis is a standard practice to obtain a larger number of CD3+ cells as a starting mate-
rial for CAR-T cell production with the goal of obtaining a minimum of 0.6 × 109 to a target 
of 2 × 109 CD3+ T cells [24]. Apheresis has the advantage and choice of extracting one or more 
components of the whole blood with help of the appropriate device and return the rest of the 
donation to the donor. Standard leukapheresis and use of anti-CD25 magnetic bead resulted 
in a yield of 130 × 106 CD4+ CD25+ T regulator (T
reg
) cells that could be expanded 8.3-fold 
over three weeks before a dose of 1 × 109 can be used for clinical trials designed to control 
HLA-mismatched GvHD or organ transplantation rejection [18]. Although the apheresis tech-
nology is available in clinical research, no advantages have been comparatively established 
to that of peripheral blood as a source. Routine production of pure immune cell specimen 
by apheresis is much more expensive (due to the costly procedure and the infrastructure 
required to carry out the intervention as well as subsequent large amounts of  antibodies 
Immune cell types# Number of cells in 200 ml of 
human blood sample (×106)
Clones of differentiation commonly 
determined for identification
Reference
Neutrophils 400–1300 CD11b+CD16+CD66b+ [14, 15]
Lymphocytes 200–600 T cells, B cells (CD3−CD19+) [16]
T cells, total 100–400 CD3+CD4+CD8+CD56− [17]
Naive T cells 40–160 CD3+CD25+CD45RA+CD45RO−
CD127+CCR7+CD62L
[17]
Memory T cells 40–160 CD3+CD56−CD45RA−
CD45RO+CCR7+CD62L+
[17]
T regulatory cells 5–20 CD3+CD4+CD25+CD127− [18, 19]
NK cells 16–80 CD3−CD16+CD56+ [20]
NKT cells 0.4–5 CD1d+CD4+CD161+ [21]
Dendritic cells 4–12 CD11c+HLA−DR+CD3−CD19−
CD80+CD86+
[22]
Monocytes 40–180 CD14+CD16+CD64+ [23]
Table 2. Prevalence of immune cells in blood of healthy donors and surface marker normally used for their identification.
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needed for purification of specific cell types from the large number of cells). Another study 
from Germany reported that ~1010 PBMC from leukapheresis result in about 8% of NK cell 
yield using Clinimacs (Miltenyi) for further GMP therapeutic expansion [20]. Difference 
between ex vivo expanded cells for cytokine-induced cell therapy for hepatocarcinoma from 
apheresis and PBMC-derived cells has been reported [25], but this needs further evaluation 
for a comparative conclusion for various cell types. The initial procedure of cell collection may 
have an influence on the biological effects of the final cell product.
The whole PBMC fraction consists mainly of T cells (naive and memory CD3+/CD56− T cells, 
mostly of central T memory type). A minor part of the PBMC contained NK cells identified as 
CD3−/CD56+ cells. Isolation and ex vivo expansion of CD3+/CD56− T cells or CD3−/CD56+ NK 
cells (and even other specific cell types in patients’ PBMC) to bigger numbers does not pose 
a big problem. It is crucial that T cells are only effective against a cancer cell type or an infec-
tious agent when specifically activated prior to infusion. Hence, T cells, NK cells, and other 
PBMC-derived cells have to be separated in the first instance and then specifically activated/
primed during the expansion process. Presentation of peptides or epitopes from tumor cells 
or micro-organisms to T cells ex vivo, directly or mediated by dendritic cells, and subsequent 
ex vivo expansion was evaluated over prolonged period of time with no or only limited suc-
cess in in vivo efficiency. Ex vivo expanded NK cells showed similar negative results, even 
when applied to patients in greater numbers [26]. It was recognized that (in blood of patients 
contained) T regulatory cells do strongly inhibit lytic power of T cells and NK cells. However, 
this seems not the only reason for disappointing results with only T cell or NK cell fractions.
It is being increasingly recognized that particularly in cancer treatment, breakthrough can be 
achieved with specific activation and expansion of sub-clones of T cells and/or defined NK 
cells ex vivo. The PBMC-derived cells must be specifically stimulated during expansion which 
can only be realized by sophisticated integration of steps in the process (either positive or 
negative selection of unwanted cells through antibodies; enhanced growth of cells of interest 
through speeding up their mitotic division). In case of T cells as much as possible, effector T 
cell clones should be present at least in the expanded population with capabilities to persist 
and execute its desired functions [27]. Expanded NK cells should express high cytotoxicity 
against patient’s tumor cells or infected cells. Specific activation has to be induced during the 
initiation steps by specific coatings of the surface of the culture flasks/container/bioreactor as 
well as by addition of different cytokines and growth factors in the medium during the subse-
quent expansion phase [6, 28, 29]. Cultivation of larger numbers of immune cells under those 
conditions is often challenging and can scarcely be realized in culture flasks.
A general belief is that a basic prerequisite for a therapeutic application of immune cell 
types is the provision of adequate number of cells. It is assumed that about 1010 of effec-
tive immune cells must be used for treating cancer or infections [1]. A tumor or metastasis 
of 1 cm3 size yields around 109 cells. In the common cytotoxicity assays using effector ver-
sus target cells, five to tenfold more effector cells are often needed to destroy one tumor or 
infected cell. However, such ex vivo results might lead into wrong direction. It is crucial that 
the cells should have strong binding ability and be armed with specific cytotoxicity against 
the target cells. Meanwhile, it is apparent that it is important to know how to select, activate, 
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trigger, and/or prime and expand immune cells ex vivo. Single T cell clones being trained 
already in vivo against mutated patients’ tumor cells or infected cells are normally present 
in PBMC only in very low numbers, but they can destroy tumor or infected cells manifold 
[30]. Concerning T cells, identifying and isolation of specific sub-clones and ex vivo expan-
sion of those clones should get more attention in the future research. Besides there are strong 
hints that treatment with immune cells can be successful only when a systemic response of 
the total immune system in a patient is achieved along with the local response in the lesions 
[31]. These are extremely important aspects in the context of production technology enabling 
to manufacture adequate effective immune cell type for optimal treatment of a patient and 
a holistic analytical follow up of systemic profiling of the patient in order to gain further 
insights to iteratively make the process more efficient.
In recent times, the isolation of TIL from tissue and/or microenvironment has proven a much 
more promising way to get access to T cells being already specifically activated by antigens/
epitopes shed from/presented by cells of solid tumors or metastases they are originating from. 
Generation of TIL seems no longer a problem. Resected parts of tumor tissues taken by tumor 
biopsies or from the microenvironment of a tumor is the method of choice, and different 
suited techniques have been published [32, 33]. It is yet not evident whether devices for stan-
dardized processing for cell suspension from the initial tumor tissue by mechanical disper-
sion and/or additional treatment with enzymes are of advantage [34, 35]. Expansion of TIL 
even in bigger numbers is possible; up to 1010 can be grown in common media supplemented 
with serum or thrombocyte lysate and specific cytokines (see Table 4). Long time expanded 
TIL often contain CD3+/CD4+/CD8+TIL. Deeper FACS analyses make likely that sub-clones 
are contained which are primed and directed against some single mutated clones [30].
Currently, there has been a major interest in genetically manipulated T cells, which can be 
transduced with chimeric antigen receptors (CAR). These CAR-T cells express this single 
chain antigen-binding domain (scFv), which ideally binds to a tumor-associated antigen 
(TAA). The CAR-T cell/tumor-binding reaction induces an activation signal in the T cells 
strong enough to destroy tumor cells completely, and contrary to normal T cells, the cytotoxic 
power of CAR-T cells is not suppressed when CAR-T cells are administered in vivo. However, 
CAR-T cells often elicit a dangerous cytokine storm. This potential adverse effect and the dif-
ficult complex and costly construction of efficient CAR-T cells seems to inhibit fast progress 
with this promising cell therapy [41–43].
Natural killer (NK) cells are getting more and more attention in the ATMP field, fighting 
cancer and infections since these innate immune cells can be successfully expanded not only 
in greater numbers but also in high degree of purity [41–43]. In contrast to T cells, NK cells 
do not feature immunological incompatibility when administered in haploidentical or even 
allogenic clinical trials. It is, however, important that NK cells in such settings are totally 
free from T cells. Advanced production technology makes NK cells attractive to use them 
in broader clinical perspective. Pure NK cells have shown nearly no unwanted side effects 
in clinical trials even when administered in high doses. The modern production processes 
deliver NK cells with enhanced functionalities (high cytotoxicity against many cancer cells 
in ex vivo tests, enhanced paracrine production). Pure NK cells can be manufactured in an 
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easy-to-handle closed system as ATMP in clinical settings near to patients [44, 45]. A particu-
lar advantage is that mass amounts of individual NK cells can be produced in a relatively 
inexpensive way due to low costs for selection, medium, activation, compared with other 
functionalized immune cells. NK cells can be expanded 2000–50,000-fold in designated per-
fusion bioreactors, whereas that has by far not been achieved in culture flasks. Adjuvant 
treatment of stem cell-transplanted patients with pure NK cells becomes a common clinical 
practice. NK cells isolated from donor blood and expanded effectively avoid infections and 
GvHD when applied immediately following transplantation.
Common sources for isolation of MSC are bone marrow aspirate, cord blood, and pieces of 
umbilical cord/placenta tissue/adipose tissue. MSC were originally identified in the 1970s 
from cellular suspensions from spleen and bone marrow by their capacity to adhere to plas-
tic—which is still the standard form to culture MSCs and also by their ability to form colo-
nies from single cells (explanted ex vivo), their fibroblast-like appearance and their capacity 
to differentiate into fat, cartilage, and bone. MSC are defined by surface markers of CD105, 
CD90, and CD73 expression, yet not CD45, CD34, and CD14 as of the consensus of ICSCT 
working group [46]. Recently, ICSCT also have defined a broad consensus of the international 
standards for harmonized potency assays to boost the clinical development of ATMP MSC 
therapy for many unmet clinical needs despite different tissue sources and disparate culture 
expansion protocols. Three preferred analytic methods in a matrix assay approach, namely, 
quantitative RNA analysis of selected gene products; flow cytometry analysis of functionally 
relevant surface markers, and protein-based assay of secretome have been proposed to reflect 
on the immunomodulatory potential of the ATMP cells for different clinical therapeutics as 
well as to evolve the regulatory landscape for the sake of the progress in the field [47].
Several techniques are employed for liposuction used for adipose tissue-derived stromal cell 
collections [48]. Processed lipoaspirate (LPA) contains multipotent cells that can be an alter-
nate stem cell source to bone-marrow-derived MSCs. LPA contains stromal vascular fraction 
(SVF) containing a number of different cell types such as adipose stromal cells (ASC), peri-
cytes, endothelial cells, fibroblasts, preadipocytes, and hematopoietic stem cells. ASC have 
differentiation potential to myogenic, osteogenic, chondrogenic, or adipogenic on culturing 
with specific induction media [49]. SVF contains a lot of vascular cells and hematopoetic cells 
that have to be eliminated before expansion of remaining MSC.
For the isolation of MSC adherence of these cells, plastic surfaces are used. The usual proce-
dure is to put the starting material into culture flasks or discs. After 10–20 days, nonadher-
ent cells are washed out, and the adhered MSC colonies are passaged, suspended in a fresh 
medium, and seeded in new flasks for further expansion. Thus, expanded MSC have been used 
in all clinical trials (see Table 7). The unavoidable detaching procedures of MSC at passaging 
influence the receptor quality of MSC. Long-term cultivation of big numbers of MSC in biore-
actors is possible and the provision of large seeding areas avoids unwanted differentiation of 
expanded MSC [54–57]. Procedures have been worked out to proceed directly into the expan-
sion phase of MSC. Outgrowth and isolation of MSC can be successfully performed by giving 
BM aspirate into the sterile plastic vessels of perfusion bioreactors. MSC from BM aspirate are 
not only diverse tumor tissue preparations but can also be placed directly in ZRP meander per-
fusion bioreactors. MSC colonies or outgrown TIL from tumor tissue pieces can then further be 
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expanded to big numbers of both cell types in the same bioreactor system under totally closed 
conditions (unpublished results with ZRP meander type bioreactors, Zellwerk, Germany).
The reports about the ever-used methods in the clinical trials do not always contain complete 
descriptions of the processes and show inconsistencies. However, in general, it can be seen 
that high-fold expansion as well as big numbers of cells have only been achieved when irradi-
ated feeder cells are used. This might be tolerable during a developmental phase of immune 
cell therapeutics but should be overcome in case of ATMP manufacturing. In ZRP perfusion 
bioreactors it was shown that individual immune cell specimen can be expanded to therapeu-
tic amounts without irradiated feeder cells.
4. Quantity and quality of T cells, TIL, and CAR-T used in  
acknowledged clinical trials
T cells are the most powerful immune cells. Despite the immense research on these cells 
enriching our deeper knowledge into T cell biology as well as their kinetics in health and dis-
eases, the different T cell subsets are yet not routinely used as cell therapeutics. This is at least 
partly due to the complex nature of immune cells and many unsolved technical problems to 
produce and handle them. In Tables 3–5, some parameters have been compiled giving insight 
into methods and technologies as well as expansion success and purity of the different T cell 
types being used in clinical trials. The chosen examples in the tables are representative of the 
field and enlighten the diversity of production processes and produced cell specimen, and 
it explains probably in part the inconsistent and predominantly unsatisfying clinical results 
with more or less identical cell specimens.
Vaccination with dendritic cells being ex vivo treated with proteins or peptides from tumor 
cells or micro-organisms as well as present target-specific peptides to T cells ex vivo, directly 
Cell source; 
supplements; 
activation
Expansion 
device used
Cultivation 
time (days)
Expansion by 
x-fold
Cell harvest Cell purity (%) Reference
PBMC/apheresis 
isolated by αCD3+ 
coated dynabeads, 
exp with IL2/αCD28
Wave system 13 101 1.37 × 1011 T 
cells
98.5% CD3+ [27]
PBMC Flask 14 169 33 × 108 62% [58]
PBMCs/apheresis 
CD25+Tregs depl, 
Stim with autol 
DC pulsed MART 
peptides, suppl IL2, 
IL7, IL21, CD8+ CTL 
sorted, exp Rapid 
Exp Prot
Flask 42 n.a. n.a. n.a. [59]
Table 3. Manufacturing processes of T cells in clinical trials (n.a.= not available).
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or mediated by dendritic cells, and subsequent ex vivo expansion is used over a long time, and 
there are even a few cell therapeutics on the market. However, adjuvant treatment in differ-
ent conditions of cancer in clinics show only limited success. In recent times, the isolation of 
TILs from tissue and/or microenvironment of solid tumors and expansion of TILs ex vivo has 
proven a much more promising way to get specific activated T cell in larger amounts.
From Table 3, it can be observed that the fold expansion in flasks and Wave bioreactor is simi-
lar, although the total number of T cells harvested differs enormously. Whether the (apheresis 
Cell source; 
supplements; 
activation
Expansion 
device used
Cultivation 
time (days)
Expansion by 
x-fold
Cell harvest Cell purity (%) Reference
TIL, IL2, serum, 
feeder cells
Bag >14 1041 5 × 1010 n.a. [36]
TIL, IL2, serum, 
feeder cells, 
anti-CD3
Flask
Wave
24 72
228
0.4 × 1010
1.5 × 1010
35 + 52
CD4 + CD8
35 + 63
[37]
TIL (6x GRex10)
TIL, IL2,
GRex
Flask
29 180
170
NA 62–72
CD3+ CD8+
62
[38]
TIL, IL2, feeder 
cells, anti CD3
Bag
Wave
>21 1259
1130
4.5 × 1010
1.5 × 1010
CD3+: F = W
CD4+: F > W
CD8+: F < W
[39]
TIL, IL2, feeder 
cells, anti CD3
Flask
Wave
>14 1433
5576
NA >97 [40]
TIL, serum, 
feeder cells, anti 
CD3, IL2, IL 15, 
IL21
ZRP Meander 
bioreactor
>20 5000 2 × 109 CD8: ~60%
CD4: 38%
(High% Tem)
Own 
data, not 
published
Table 4. Manufacturing processes of TIL in clinical trials (n.a.= not available).
Cell source; 
supplements, 
activation
Expansion 
device used
Cultivation 
time (days)
Expansion by 
x-fold
Cell harvest Cell purity (%) Reference
PBMC, anti-CD3, 
IL-2, feeder cells, 
serum
Well plates 14–24 n.a. n.a. (infusion: 
≤1010)
n.a. [41]
PBMC, anti-CD3, 
anti-CD28
Bag 12 10.6 n.a. CD3+: >95 [43]
PBMC, anti-CD3, 
IL-2, IL-15
WAVE 35 n.a. 109 n.a. [33]
PBMC, serum, 
feeder PBMCs, 
IL-2
Bag ≤48 15.000 ~3×1011 CD4+: ≤82
CD8+: ≤85
[60]
Table 5. Manufacturing processes of CAR-T-cells in clinical trials (n.a.= not available).
Stem Cells in Clinical Practice and Tissue Engineering254
derived) large number of generally stimulated T cells was of advantage for the treated patients 
could not be evidently established from published literatures. The example of CTL expansion 
and therapeutic use did not state details of the expansion process with missing information.
To get effective, functional T cells out of PBMC expansion process have to be “conditional” 
(activation of sub-clones by specific cancer/micro-organism-derived structures; naive cell/cell 
and cell/matrix contact; preferred or suppressed growth of a cell population/sub population 
by specific cytokine/growth factor/antibody stimulation; controlled gas and nutrient supply).
It is obvious from Table 4 that the expansion of TIL even in bigger numbers is possible, up 
to more than 1010 TIL might be grown in flasks as well as in bags, G-rex flasks, Wave bioreac-
tors, or ZRP perfusion bioreactors. Media and supplements are qualitatively similar. In all 
examples, use of feeder cells seem to be essential. Looking closer into Table 4, the fold expan-
sion differs over a wide range. This implies that strongly differing numbers of TIL must have 
been isolated. G-Rex flasks is of advantage for TIL expansion by providing high O
2
 concentra-
tion near to the sedimented TIL that enhances growth. In own studies (not published) of ZRP 
meander bioreactors, O
2
 (Zellwerk, Germany) concentration can be up-regulated to find an 
optimal O
2
 value in the medium for TIL growth.
Although a lot of clinical trials with TIL have been performed so far, there is not much infor-
mation about clinical efficiency of TIL (with an exception of late-stage metastatic melanoma). 
Expanded TIL over a prolonged period often contains CD3+/CD4+/CD8+CD25+cells in differ-
ent ratios. Deeper FACS analyses make likely that subclones that are contained are primed and 
directed against some single mutated clones. Again, it must be emphasized that even with TIL 
stronger standardized cell production processes, better characterization of contained clones, 
more comparable preclinical data as well as professional designed clinical trials are needed.
The expansion of several CAR-T cell specimen seems not to be a problem (Table 5). Blood-derived 
natural T cells were used for CAR transduction. Expansion to large numbers of the CAR-T cells 
was achieved by using the same interleukin activation and culturing procedures as in the case 
of normal T cells. Some of the advanced centers are engaged in optimizing newer technologies 
including Miltenyi’s CliniMACS Prodigy as well as Zellwerk’s ZRP technology system.
5. State-of-the-art with ex vivo expanded NK cells utilized in clinical 
trials
NK cells are getting more and more attention in fighting cancer and infections since it succeeded 
to expand these immune cells not only in huge amounts but also in pure quality [4–6, 61]. In 
contrast to T cells, NK cells do not show immunological incompatibility when administered in 
haploidentical or even allogenic clinical trials. It is, however, important that NK cells in such set-
tings are totally free from T cells. In Table 6, a selection of clinical studies is listed, among them 
are those that are performed by known clinical research groups. It can be deduced that bigger 
numbers of NK cells can be produced in culture flaks as well as in some cell culture equipment 
consisting of plastic bags or vessels (VueLife static culturing in bags; wave system using differ-
ent bags, mixing of medium by slow shaking movement of the bag). The bag systems are closed 
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systems, and some of the equipment are provided with regulating and/or steering elements for 
gasing, measurement of pH, pO
2
, and medium temperature is obligatory. However, changing 
bag volumes and upscaling within a cultivation run is not easy and possible with these systems. 
One main advantage of NK cells is the good compatibility of this immune cell specimen. NK 
cells can be expanded up to 50,000-fold in suited perfusion bioreactors (Table 6), whereas this 
is by far not achieved in culture flasks. Adjuvant treatment of stem cell-transplanted patients 
with pure NK cells becomes common. NK cells isolated from donor blood and expanded avoids 
effectively GvHD when applied during the first phase after transplantation.
Advanced production technology makes NK cells attractive for use in broader bases: Pure NK 
cells have shown nearly no unwanted side effects in clinical trials even when administered in 
high doses. The modern production processes deliver NK cells with enhanced functionalities 
(high cytotoxicity against many cancer cells in ex vivo tests and enhanced paracrine produc-
tion). Pure NK cells can be manufactured in an easy-to-handle closed system as ATMP in 
 clinical settings near to patients. A particular advantage is that mass amounts of individual NK 
cells can be produced economically (due to low costs of selection, medium, and activation).
6. State-of-the-art with ex vivo expanded MSCs utilized in clinical trials
With numbers of 109 MSC, therapeutic effects were reported in the treatment of autoimmune 
and infectious diseases [68, 69]. The issue on reliabilities and logistically practical methods for 
Cell source; supplements, 
activation
Expansion device 
used
Cultivation 
time (days)
Expansion by 
x-fold
Cell purity Reference
PBMC fraction, serum; IL 2, Stirred bioreactor 
(750 ml)
33 352 96% [62]
PBMC fraction; serum; IL 2;IL 
15; PHA
VueLife bag 
system (800 ml)
14 80–200 85–91% [63]
PBMC fraction; serum; IL2/
IL12/IL15; feeder cell line
T-flaks 10 40 62–95% [64]
PBMC fraction; serum; IL 2; 
IL 15; feeder cell line K529; 4 
BBL1
VueLife bag 
system
21 277 97% [65]
PBMC fraction; medium; 
serum; IL 2
Wave bioreactor 21 12–354 37–54% [66]
PBMC fraction; medium; 
serum; IL 2; feeder cell line 
K529;
G-Rex flask 8–10 442 54–79 [67]
PBMC fraction; medium; 
serum; IL 2;
ZRP type M single-
use bioreactor
30 1000–2000 95–99% Own data, not 
published
PBMC fraction; serum; IL 2/IL 
21; coating with CD 16
ZRP typ M single-
use bioreactor
30–35 1000–50,000 99% Own data, not 
published
Table 6. NK cells for cell therapies. Different production methods.
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production of MSC for adequate amounts of immune cells needs specific attention. Most of 
the current clinical trials use open culture system in flasks even though there have been ongo-
ing efforts with newer technologies (compare Table 7).
Consistent and logistically practical methods for production of MSC for adequate numbers of 
immune cells need specific attention. In addition, there are many unresolved issues relating to the 
isolation, expansion technique, phenotyping characterization, mechanisms of action, and incom-
parability of study results due to different protocols and definitions. In most of the current clini-
cal trials, open culture system in flasks is in use (compare Table 7) even though there have been 
ongoing efforts with newer technologies [56, 70, 71]. In contrast, MSC, in particular those derived 
from bone marrow, lead candidates to fight many important disease entities. It is believed that 
modulation of immune responses, remodeling of impaired tissues, pro-regenerative as well as 
antifibrotic effects can be attained with these immune cells. With numbers of 109 MSC, effects 
were reported in treatment of some autoimmune and infectious diseases [68, 69]. A lot of clini-
cal trials have been performed or are ongoing on treating cardiovascular diseases (myocardial 
infarction, cardiomyopathy, critical limb ischemia, stroke [72–74]). Single or repeated doses of 
107 to more than 109 are injected systemically or topically. Until now, some positive influences on 
cardiovascular disease could be ensured through cytokines and chemokines secreted from MSC. 
Avoiding GvHD is also under intense investigation due to increasing stem cell transplantation 
in cancer and organ transplant patients. In all these indications, autologous or allogenic MSC are 
being infused that are not really manufactured under controlled conditions.
7. Newer techniques for characterization and production of immune  
cells therapeutics
Identification of different cell types, subpopulations, and even single subclones within a final 
cell therapeutics product can be a challenging exercise due to many constraints including the 
limited number of cells available. Immune cells are usually identified from its displayed sur-
face receptors that also gives a hint on its characters to fight infections or cancer. Cell sorting 
by flow cytometry or magnetic beads are modern techniques allowing isolation and separation 
Cell source; 
supplements
Expansion 
device used
Cultivation 
time (days)
Expansion by 
x-fold
Cell harvest Cell purity Reference
BM-MNC, serum Flasks 30 n.a. n.a. 99% [50]
BM-MNC, serum Flasks 30–45 6–52 2.4–5.7 x 107 >60% [51]
BM-E serum Five layer 
flasks
10–28 n.a. 6–27 x 107 n.a. [52]
BM-W, serum 59 
donors
Five layer 
flasks
28 5–145 2 x 107 to 5 
x 109
n.a. [53]
UC blood, serum FIve layer 
flasks
22–28 n.a. 1–8 x 108 n.a. [52]
Table 7. Manufacturing processes of MSC in clinical trials (n.a.= not available).
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of immune cell subtypes. These methods are still time-consuming and costly exercises due to 
the quantity of antibodies and reagents required in the manufacturing process when dealing 
with larger starting material such as cells derived through apheresis. GMP-grade antibodies 
are particularly costly making the ATMP cell therapy an unaffordable range.
However, it is pertinent to analyze and to predict the potency of the cells that give a prior 
indication of the anticipated possible effects of the immune cells on the intended outcome. In 
case of T cells, it has been recently accomplished by tracking the fate and origin of clinically 
relevant adoptively transferred CD8+ T cells in vivo to identify and track single subclones spe-
cifically activated against few tumor cell mutants specific T memory cells [30]. By using high-
throughput T cell receptor sequencing, the group has worked out a strategy to identify and 
track those very low frequency monoclonal T cells among the total bulk of polyclonal T cell 
pool with varying cancer-killing and fighting capabilities that have been given as adoptive 
cell therapy to 10 metastatic malignant melanoma patients being specifically activated against 
melanoma and correlated with the treatment response in patients. They were then also able to 
decipher the specific clonal population of extremely low density of T cells that were persisting 
and effective in vivo among two patients out of ten demonstrating complete remission. It is 
worth proving whether this new approach can be applied effectively in clinical practice and to 
prove its rationale in other cancer types. Only around 0.001% of all T cells in blood consisted 
of these active monoclonal T cells. This study also indicated that the younger T cells nearly in 
the phase of development had a better ability to fight tumors than older ones.
Further progress in the identification of subpopulations, primed monoclonal T cells, and 
information on functionality of cell preparations may be obtained by the spectra of single 
cells, their typical receptors/ligands/paracrine production. Raman microscopy has long been 
used in cell and metabolites analysis. However, the combination of this method with sophis-
ticated software programs with in-depth analyses tools can lead to sharper, high-resolution 
Raman spectra enabling differentiating looks onto cells enabling subtype identification, quan-
tification, analysis of functional status, etc. [10–13].
CyTOF, the latest novel format of flow cytometry combined with mass spectrometry, often 
referred as mass cytometry provides a measurement of >40 simultaneous cellular parameters 
at single-cell resolution, significantly augmenting the ability of cytometry to evaluate com-
plex cellular systems and processes at any given point. This has been a greatest tool to unravel 
the mechanism of immune cells by studying kinetics before and after infusion. Currently, 
research on solid cancers has a strong focus on immune cells infiltrations in the microenviron-
ment of tumors. In a mouse model of triple negative breast carcinoma, the new methods using 
CyTOF assessing immune cells at single cell level within the tumor in the microenvironment 
of the tumor as well systemically in different organs over time demonstrated a striking differ-
ence of the sustained response at systemic level in the effective treatment responsive group 
in comparison to the nonresponsive treatment group [31]. Local carcinoma treatment was 
followed by an infiltration of CD8+/CD4+ T cells into the tumor leading to death of tumor 
cells. Different immune cell specimens were expanded during the rejection phase not only 
in the microenvironment of the carcinoma but also in many lymphatic organs and blood to 
reflect on the changes taking place systemically. A systemic coordinated immune response of 
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CD4+ as well as CD8+ T cells, NK cells, DC cells, and activated B cells seems to be essential for 
achieving sustainable effects to eradicate tumors with immune cell therapy. This has much 
more connotation for the ATMP cell therapy to reach its full potential.
The ZRP platform of Zellwerk and the belonging bioreactor types provide sophisticated fea-
tures not only for mass production of different immune cells but also for realizing isolation 
and culturing the cells in closed processes [54–57, 70, 75]. It enables controlled phases of selec-
tion/priming/activation of seeded cells by regulated medium flow, suited coating of seeding 
surfaces and/or fixed antibodies, followed by rapid expansion, all in a single run. This is due 
to the technical attributes:
Bioreactors of the ZRP system can be operated in the GMP breeder (Figure 1). The breeder 
combines a laminar flow sterile bench and an incubator. Controlling of the essential bioreac-
tor and breeder functions is by the control unit (automatic regulation of pO
2
, pH, medium 
temperature, medium feeding, mixing, and flow of gasses over a touch screen).
The cell cultivation platform and the belonging bioreactors enable the manufacturing of large 
quantities of individual immune cell preparations under GMP conditions. A series of ZRP 
systems can be driven in parallel in one clean room equipment due to the closed steps of the 
perfusion bioreactor processes. During a period of 1 year, several immune cell preparations 
from individuals amounting to ~100 can be undertaken in one B clean room thus reducing 
expenditures for production of immune cell therapeutics massive. Manufacturing of immune 
cells as ATMP is authorized by the national and regional German authorities.
Important features of the meander type bioreactors are as follows: A directed laminar flow 
of medium, which can be chosen over a wide range, makes an undisturbed cell/cell- and 
cell/surface-contact possible and minimizes cell stress. The ratio of medium circulation and 
fresh medium flow is automatically regulated over time by a chosen algorithm guaranteeing 
ananan consistent homogenous supply with nutrients and gasses as well as precise regulated 
pO
2
, pH, and temperature in the medium. T cells, TILs, and NK cells can be expanded to 
more than a 1010 cells in one closed cultivation run. In parallel cultivation run with pure NK 
Figure 1. Zellwerk’s GMP Z®RP cell breeder with M type bioreactor for NK/T/TIL cells.
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cells using the same medium and density of seeded cells, expansion in static flasks was not 
more than 50–100-fold, whereas in meander type bioreactor 5000–50,000-fold was achieved. 
Coating of seeding areas with specific matrices/antibodies, i.e., can be exploited to promote 
suppression or expansion of several immune cell specimen (e.g., Treg; CD56bright NK cells).
8. Current advances and future prospects
Despite many clinical trials with immune cell therapy and much progresses in the field, the 
manufacturing of cells as ATMP for routine clinical use has not been realized in its full poten-
tial. Here we attempt to give an overview of different advanced technologies and devices cur-
rently available for cell expansion. These different devices need to be validated and compared 
in head-to-head comparison for different cell type to exploit the opportunities for unmet clini-
cal needs.
Sterility, purity, identity, and potency are four cardinal requirements. Initially, cell expan-
sions have been carried out in the conventional process of open flask culture system with 
gradual incremental innovations to meet the growing needs of regulatory requirements as 
well as better quality products in terms of safety (phenotype), consistency (reproducibility 
and controlled robust process), numbers, quality (structural and functional), and efficacy 
(functionality and potency) to qualify as ATMP to be used in patients/human subjects. From 
simple culture flasks, multilayered flask was made for ease of handling as well as scaling up 
with the numbers (such as Millicell, Millipore or BD Multiflask).
Different microcarrier system came into place to increase surface area to expand cells in 3D 
than in flasks in 2D [76–78]. G-Rex system is a gas permeable rapid expansion device with a 
silicone membrane at the base, allowing gas exchange to occur uninhibited by the depth of the 
medium above with high O
2
 concentration stimulating cell expansion and simplify handling 
[99]. WAVE-type bioreactor systems [79] make use of sterile, transparent, and disposable cul-
ture bags with provision for media perfusion, harvest, sampling, and gas exchange, which 
greatly reduces the cross-contamination problem, one of the biggest challenge in conventional 
culture system [37, 38]. The culture bag is put on the device’s temperature-controlled tray 
inside an incubator having the option of controlled rocking movement. Optional perfusion 
modules enable controlled addition and removal of culture media for optimized nutrient con-
centrations while disposing spent media resulting in higher cell densities with involvement of 
less time and effort for media exchange. Magnetic beads are used in the bag for various prim-
ing and activation of cells [80]. However, the chaotic medium flow causes cell stress [78, 79]. 
These factors have been well addressed in ZRP cell breeder that has controlled and directed 
medium flow and fulfills most of the regulatory requirements (see Section 7).
MILTENYI’s CliniMACS Prodigy® [81] is an automated integrated sensor-controlled closed 
system device that uses single-use sterile disposable tubing set and can perform fractionation 
of cells, cell washing, cell separation, cell culture, and final product formulation in the work-
flow connected through sterile docking devices. TERUMO quantum system is a functionally 
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closed automated hollow fiber bioreactor system for GMP cell manufacturing that has been 
tried in MSC expansion [82]. Huge efforts are ongoing in Japan to build modular robotics-
manipulated, automated high-throughput cell-processing machine to make off-the-shelf cell 
therapy products for wider application [83].
Product dictates the process development and optimization to ensure cost-effectiveness, well-
controlled steps, high reliability, high cell density and viability, high product quality, easy 
recovery, high yield, and high safety for personnel. Perfusion system takes care of controlled 
dynamic gas exchange with a homogenous environment allowing high cell density with con-
trollable and flexible process control, but demands complicated validation procedure.
Evolving regulatory landscape for ATMPs (cell therapy) [84–87] has the following two man-
dates to be fulfilled (quoted from EMA document [88]):
• Cells or tissues that have been subjected to substantial manipulation so that biological char-
acteristics, physiological functions, or structural properties relevant for the intended clini-
cal use have been altered, or of cells or tissues that are not intended to be used for the same 
essential function(s) in the recipient and the donor.
• Have properties for, or are used in or administered to human beings with a view to treat-
ing, preventing, or diagnosing a disease through the pharmacological, immunological, or 
metabolic action of their cells or tissues.
Regulatory landscape for ATMP cell therapy at this juncture is quite diverse in various regions 
of the world and is evolving though in a gradient [89–95]. It is a daunting task, but is an abso-
lute necessity to harmonize all the harmonizers (regulatory bodies) across the globe with an 
unified coherent process to make ATMP cell therapy possible for unmet clinical needs. The 
regulatory bodies have the responsibilities to assure the safety and rights of patients and to 
ensure quality of the nonclinical and clinical evidences to allow appropriate evaluation of the 
safety and effectiveness of the cell therapy product through clinical trials for market autho-
rization. FDA and EMA have distinct guidelines, whereas there are distinct guidelines in 
other parts such as Australia, Brazil, Japan, Korea, Singapore, and Taiwan just to give a flavor 
of the unique differences that pose constraints in the current clinical development of ATMP 
cell therapy. While such efforts to converge on an unified regulatory process are underway 
through engagements, two critical issues have been identified to be addressed, the concept of 
potency assessment as well as in vivo tumorigenicity studies [96].
FDA has developed a number of expedited programs to facilitate ATMP cell therapy use 
in patients when no satisfactory alternative therapies are available while ensuring the stan-
dards of the products for safety and efficacy. EMA made a new regulation in 2009 for all 
28 member countries in EU with obligatory centralized market authorization process. Eight 
cell therapy ATMPs have been authorized in EU [97], namely ChondroCelect (withdrawn in 
January 2017) and Maci (suspended from July 2014 due to closure of European manufactur-
ing unit), both the products are autologous cartilage cells grown ex vivo for cartilage repair; 
Provenge (autologous PBMC activated with fusion protein of prostatic acid phosphatase 
attached to GM-CSF ex vivo) for treatment of advanced prostate cancer, withdrawn in May 
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2015; Holoclar, autologous limbal stem cells to repair damaged corneal epithelium, this has 
orphan drug status due to rare condition. A great deal of effort are underway in EMA to 
refine and execute adaptive regulatory pathway to foster rapid development and acceler-
ated assessment for innovative cell therapies. Korea has 14 cell products authorized includ-
ing four stem cell products with 46 ongoing clinical trials with other cell therapy products. 
New adaptive regulatory framework has been enacted under the Pharmaceuticals, Medical 
Devices and Other Therapeutic Products Act (PMD Act) in Japan in late 2014 to facilitate 
access of promising ATMP cell therapy to the patients with limited treatment options as well 
as creating conducive regulatory environment to give accelerated conditional and time-lim-
ited authorization to stimulate further clinical development. Two products namely, MSC for 
GvHD second-line therapy and skeletal myoblast sheets for ischaemic heart failure have been 
authorized under the new scheme in 2015 and 2016.
Since cell culture uses animal-derived serum or growth factors, the sources need to be certi-
fied and proven free of any adventitious agents, consistent in quality and free of risk of any 
possible infections.
First ATMP cell therapy product to get market approval was in Canada for Prochymal 
(Remestemcel-L), adult MSC for IV infusion for acute GvHD in May 2012. Allogeneic adipose 
tissue-derived MSC expanded ex vivo have been shown efficacious in Phase 3 clinical trial 
when given intra-lesionally in complex perianal fistulas in Crohn’s disease patients and a 
decision is awaited in 2017 for market authorization by EMA. This product named as Cx601 by 
Takeda and TiGenix has received orphan status by the Swiss Agency for Therapeutic Products 
(Swissmedic) for the rare disease. While these innovations are taking place at immense pace, 
there is growing requirement of policymakers to be engaged along with patients’ community 
to see how best a value-based frameworks and be drawn as rational approaches to use these 
expensive novel therapeutic modalities in patient care [98].
9. Conclusion
The manufacturing of immune cells is until today primarily performed using archaic, scarcely 
controlled, incomparable processes and methods. These issues need to be better harmonized 
and put into standard practice. When looking into the processes of immune cell production 
used in clinical studies, it is obvious that the cells in most settings are expanded totally or 
partly in conventional culture flasks or similar vessels. That is due to the fact, that all immune 
cell types can be grown in this simple and cheap way without special skills. However, deeper 
characterization of ex vivo expanded immune cells is urgently needed not only on the level 
of a few receptors and ligands on the cell surface but also with respect to the ever-contained 
subtypes in an expanded immune cell population, the pattern of secreted effector molecules, 
their amounts over time and influences from in vivo components on them.
More research on aspects of modern cell therapy might be qualified as too costly, but will be 
more targeted and will at least avoid expensive and unjustified clinical studies maximizing 
the best use of the available R&D resources for better outcomes.
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